GlassScriptPhysician profile
Kayla Myers
NPI 1740807882
$6,829.08
in general payments reported to CMS, 2019-2025
29 companies · $3,398 in 2025
The $3,398 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $711 · 2023: $1,211 · 2024: $1,510 · 2025: $3,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,944 · Travel and Lodging: $1,094 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,944.25 |
| Travel and Lodging | $1,094.01 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,939.71 | 2024-2025 | Inspire |
| Verona Pharma, INC. | $505.59 | 2025 | Ohtuvayre |
| Glaxosmithkline, LLC. | $505.37 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $480.53 | 2022-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $396.30 | 2023-2025 | Dupixent |
| Mylan Specialty L.P. | $383.98 | 2022-2024 | Yupelri |
| Grifols USA, LLC | $341.74 | 2022-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.89 | 2022-2025 | Ofev, Stiolto Respimat |
| United Therapeutics Corporation | $283.92 | 2022-2025 | Tyvaso, Tyvaso |
| Harmony Biosciences LLC | $227.82 | 2022-2025 | Wakix |
| Genzyme Corporation | $221.03 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $163.70 | 2023-2025 | Glassia |
| Actelion Pharmaceuticals US, INC. | $160.28 | 2023-2025 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $139.60 | 2022-2025 | |
| Pulmonx Corporation | $124.66 | 2023-2025 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $98.49 | 2023-2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $72.11 | 2023-2024 | |
| Azurity Pharmaceuticals, INC. | $70.07 | 2024 | Horizant |
| Baxter Healthcare | $64.84 | 2022 | |
| Insmed, INC. | $53.44 | 2022-2025 | Arikayce |
| Amgen INC. | $45.66 | 2024-2025 | Tezspire |
| Paratek Pharmaceuticals, INC. | $45.52 | 2024-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $39.29 | 2024 | Winrevair, Keytruda |
| Lilly USA, LLC | $37.64 | 2025 | Zepbound |
| Mallinckrodt Hospital Products INC. | $32.13 | 2022-2024 | Acthar |
| Avadel Cns Pharmaceuticals, LLC | $30.39 | 2024 | Lumryz |
| Viatris Specialty LLC | $25.66 | 2025 | Yupelri |
| Impulse Dynamics (USA) INC. | $23.63 | 2022 | |
| Ani Pharmaceuticals, INC. | $23.09 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Myers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.